Michael Hallek to Female
This is a "connection" page, showing publications Michael Hallek has written about Female.
Connection Strength
0.174
-
Long-Term Studies Assessing Outcomes of Ibrutinib Therapy in Patients With Del(11q) Chronic Lymphocytic Leukemia. Clin Lymphoma Myeloma Leuk. 2019 11; 19(11):715-722.e6.
Score: 0.011
-
Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials. Anticancer Res. 2019 May; 39(5):2591-2598.
Score: 0.011
-
CLL2-BIG: sequential treatment with bendamustine, ibrutinib and obinutuzumab (GA101) in chronic lymphocytic leukemia. Leukemia. 2019 05; 33(5):1161-1172.
Score: 0.011
-
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018 09; 19(9):1215-1228.
Score: 0.010
-
A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood. 2018 03 01; 131(9):955-962.
Score: 0.010
-
Lenalidomide maintenance after first-line therapy for high-risk chronic lymphocytic leukaemia (CLLM1): final results from a randomised, double-blind, phase 3 study. Lancet Haematol. 2017 Oct; 4(10):e475-e486.
Score: 0.010
-
Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood. 2017 05 11; 129(19):2702-2705.
Score: 0.009
-
Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial. Blood. 2016 Jan 14; 127(2):208-15.
Score: 0.009
-
The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia. Future Oncol. 2015; 11(1):51-9.
Score: 0.008
-
Providing care in isolation while awaiting SARS-CoV-2 test results: Considering differential diagnoses and avoiding anchoring bias. Medicine (Baltimore). 2021 Jul 30; 100(30):e26720.
Score: 0.003
-
Detection of SARS-CoV-2 viremia before onset of COVID-19 symptoms in an allo-transplanted patient with acute leukemia. Bone Marrow Transplant. 2021 03; 56(3):716-719.
Score: 0.003
-
COVID-19 among fit patients with CLL treated with venetoclax-based combinations. Leukemia. 2020 08; 34(8):2225-2229.
Score: 0.003
-
COVID-19 associated pulmonary aspergillosis. Mycoses. 2020 Jun; 63(6):528-534.
Score: 0.003
-
Characteristics and course of patients with advanced hematologic malignancies receiving specialized inpatient palliative care at a German university hospital. Ann Hematol. 2019 Nov; 98(11):2605-2607.
Score: 0.003
-
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia. J Clin Oncol. 2019 06 01; 37(16):1391-1402.
Score: 0.003
-
Sequential therapy for patients with primary refractory acute myeloid leukemia: a historical prospective analysis of the German and Israeli experience. Haematologica. 2019 09; 104(9):1798-1803.
Score: 0.003
-
HBsAg-negative/anti-HBc-positive patients treated with rituximab: prophylaxis or monitoring to prevent hepatitis B reactivation? Infection. 2019 Apr; 47(2):293-300.
Score: 0.003
-
Evaluation of the CLL-IPI in relapsed and refractory chronic lymphocytic leukemia in idelalisib phase-3 trials. Leuk Lymphoma. 2019 06; 60(6):1438-1446.
Score: 0.003
-
Somatic alterations in circulating cell-free DNA of oesophageal carcinoma patients during primary staging are indicative for post-surgical tumour recurrence. Sci Rep. 2018 10 08; 8(1):14941.
Score: 0.003
-
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. Leuk Lymphoma. 2019 03; 60(3):649-657.
Score: 0.003
-
Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer. Oncogene. 2018 10; 37(42):5682-5693.
Score: 0.003
-
Effects of Kyusho Jitsu on Physical Activity-levels and Quality of Life in Breast Cancer Patients. In Vivo. 2018 Jul-Aug; 32(4):819-824.
Score: 0.003
-
Comprehensive Safety Analysis of Venetoclax Monotherapy for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia. Clin Cancer Res. 2018 09 15; 24(18):4371-4379.
Score: 0.003
-
Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. Cancer Res. 2018 08 01; 78(15):4270-4281.
Score: 0.003
-
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal Trial. J Clin Oncol. 2018 07 01; 36(19):1973-1980.
Score: 0.003
-
Unmanipulated haploidentical in comparison with matched unrelated donor stem cell transplantation in patients 60 years and older with acute myeloid leukemia: a comparative study on behalf of the ALWP of the EBMT. J Hematol Oncol. 2018 04 16; 11(1):55.
Score: 0.003
-
Effects of physical exercise on breast cancer-related secondary lymphedema: a systematic review. Breast Cancer Res Treat. 2018 Jul; 170(1):1-13.
Score: 0.003
-
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia. Nat Commun. 2018 02 20; 9(1):727.
Score: 0.003
-
Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL. Nat Commun. 2018 02 15; 9(1):697.
Score: 0.003
-
The preventive effect of sensorimotor- and vibration exercises on the onset of Oxaliplatin- or vinca-alkaloid induced peripheral neuropathies - STOP. BMC Cancer. 2018 01 10; 18(1):62.
Score: 0.002
-
Outcomes of haploidentical stem cell transplantation for chronic lymphocytic leukemia: a retrospective study on behalf of the chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2018 03; 53(3):255-263.
Score: 0.002
-
On Taking a Different Route: An Unlikely Case of Malaria by Nosocomial Transmission. Clin Infect Dis. 2017 10 15; 65(8):1404-1406.
Score: 0.002
-
NFATC1 activation by DNA hypomethylation in chronic lymphocytic leukemia correlates with clinical staging and can be inhibited by ibrutinib. Int J Cancer. 2018 01 15; 142(2):322-333.
Score: 0.002
-
Early, risk-adapted treatment with fludarabine in Binet stage A chronic lymphocytic leukemia patients: results of the CLL1 trial of the German CLL study group. Leukemia. 2017 12; 31(12):2833-2837.
Score: 0.002
-
Cytogenetically cryptic ZMYM2-FLT3 and DIAPH1-PDGFRB gene fusions in myeloid neoplasms with eosinophilia. Leukemia. 2017 10; 31(10):2271-2273.
Score: 0.002
-
Allogeneic hematopoietic cell transplantation for high-risk CLL: 10-year follow-up of the GCLLSG CLL3X trial. Blood. 2017 09 21; 130(12):1477-1480.
Score: 0.002
-
Impact of gender on outcome after chemoimmunotherapy in patients with chronic lymphocytic leukemia: a meta-analysis by the German CLL study group. Leukemia. 2017 10; 31(10):2251-2253.
Score: 0.002
-
Rare germline variants in ATM are associated with chronic lymphocytic leukemia. Leukemia. 2017 10; 31(10):2244-2247.
Score: 0.002
-
Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clin Cancer Res. 2017 Sep 01; 23(17):5292-5301.
Score: 0.002
-
Economic burden of clinical trials in lung cancer in a German Comprehensive Cancer Center. Lung Cancer. 2017 06; 108:134-139.
Score: 0.002
-
Defects of beta 2-adrenergic signal transduction in chronic lymphocytic leukaemia: relationship to disease progression. Eur J Clin Invest. 1997 Feb; 27(2):121-7.
Score: 0.002
-
Treatment of older patients with mantle-cell lymphoma. N Engl J Med. 2012 Aug 09; 367(6):520-31.
Score: 0.002
-
Due to low infection rates no routine anti-infective prophylaxis is required in younger patients with chronic lymphocytic leukaemia during fludarabine-based first line therapy. Br J Haematol. 2007 Jan; 136(1):63-72.
Score: 0.001